Get the Stockscreener App
52.80
0.88%
0.46
After Hours:
52.80
Cytokinetics Inc stock is traded at $52.80, with a volume of 1.05M.
It is up +0.88% in the last 24 hours and down -7.50% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$52.34
Open:
$52.1
24h Volume:
1.05M
Relative Volume:
0.79
Market Cap:
$6.21B
Revenue:
$3.13M
Net Income/Loss:
$-545.28M
P/E Ratio:
-9.5652
EPS:
-5.52
Net Cash Flow:
$-401.27M
1W Performance:
+1.36%
1M Performance:
-7.50%
6M Performance:
-24.69%
1Y Performance:
+79.23%
1-Day Range:
$51.66
$52.96
1-Week Range:
$51.47
$53.94
52-Week Range:
$25.98
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics CEO sells $260,700 in company stock - Investing.com
Cytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting - StockTitan
Clearline Capital LP Has $11.25 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions - StockTitan
Darwin Global Management Ltd. Invests $246.07 Million in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Marshall Wace LLP Sells 878,644 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Trimmed by Murchinson Ltd. - MarketBeat
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program - StockTitan
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Davidson Kempner Capital Management LP Purchases 89,563 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
15,835 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Acquired by Edgestream Partners L.P. - MarketBeat
Massachusetts Financial Services Co. MA Acquires Shares of 276,067 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Renaissance Technologies LLC Acquires 105,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting - Yahoo Finance
Insider Sale: EVP Research & Development Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics (NASDAQ:CYTK) Trading Down 3.2% - MarketBeat
Cytokinetics executive sells over $400k in company stock By Investing.com - Investing.com South Africa
Cytokinetics executive sells over $400k in company stock By Investing.com - Investing.com Australia
Cytokinetics executive sells over $400k in company stock By Investing.com - Investing.com Canada
Cytokinetics executive sells over $400k in company stock - Investing.com
Cytokinetics executive sells over $400k in company stock By Investing.com - Investing.com UK
WINTON GROUP Ltd Acquires New Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics' (NASDAQ:CYTK) investors will be pleased with their massive 333% return over the last five years - Simply Wall St
Cytokinetics's Options Frenzy: What You Need to Know - Benzinga
Thornburg Investment Management Inc. Boosts Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics executive sells $274,600 in stock, buys $108,050 worth By Investing.com - Investing.com Australia
Cytokinetics executive sells $274,600 in stock, buys $108,050 worth - Investing.com
Cytokinetics executive sells $274,600 in stock, buys $108,050 worth - Investing.com India
Cytokinetics executive sells $274,600 in stock, buys $108,050 worth By Investing.com - Investing.com Canada
Cytokinetics executive sells $274,600 in stock, buys $108,050 worth By Investing.com - Investing.com UK
Hypertrophic Cardiomyopathy Market Forecasted to Surge - openPR
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study - AOL
Goldman Sachs maintains Neutral on Cytokinetics with consistent price target By Investing.com - Investing.com Canada
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study - Yahoo Finance
Cytokinetics set for phase 2 trial of heart drug after study - Investing.com Canada
H.C. Wainwright keeps Buy rating on Cytokinetics shares on HFpEF treatment data - Investing.com Canada
TD Asset Management Inc Raises Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - Markets Insider
Cytokinetics set for phase 2 trial of heart drug after study - Investing.com UK
Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - StockTitan
Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds? - Yahoo Finance
Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds? - Insider Monkey
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting - StockTitan
ESC-ape velocity? Cytokinetics revs HCM case with aficamten - BioWorld Online
SEQUOIA-HCM Substudy Details Effects of Aficamten on Cardiac Structure and Remodeling - MD Magazine
Cytokinetics shares gain as JPMorgan raises price target By Investing.com - Investing.com Canada
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
JMP Securities Reaffirms "Market Outperform" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Heart Drug Boosts Exercise in Hypertrophic Cardio Trial - Mirage News
Cytokinetics executive sells over $420k in company stock By Investing.com - Investing.com Australia
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):